For decades, women’s health has been treated as a niche within healthcare—investment, research intensity, and commercial urgency have rarely matched the scale of need. That mismatch is no longer tenable demographically or economically: aging populations and rising expectations for quality of life make menopause-related care a durable market with decades of growth ahead.
The issue is not simply ‘more products.’ It is better evidence, clearer endpoints that reflect women’s priorities, and formulations that fit real-world adherence. Where innovation aligns with those fundamentals, outcomes improve—and economics follow.
JASTLabs exists to operate at that intersection: rigorous pharmaceutical development aimed at FDA-quality proof, paired with a thesis that serving women well is compatible with building lasting shareholder value. Public ownership, for us, is a mechanism to align long-term incentives with long-term patient benefit.
Industry peers can do more than issue statements. They can fund trials, diversify pipelines, and compete on outcomes. We intend to lead by example—and we invite stakeholders who share that standard to follow our disclosures closely as we execute.